In this free webinar, learn about conjugation methods, applications and clinical progress of small nucleic acid drug conjugates. Attendees will gain insight into the characterization of conjugated ...
(Nasdaq: ALNY), a leading RNAi therapeutics company, is presenting new today from its GalNAc-conjugate siRNA programs for the systemic delivery of RNAi therapeutics at the XX International Roundtable ...
PHILADELPHIA--(BUSINESS WIRE)--Aro Biotherapeutics, a clinical stage biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced upcoming data presentations ...
- Conjugation of 2’-O-hexadecyl (C16) to siRNA Enables Therapeutic Silencing of Target Genes Outside the Liver with Infrequent Dosing in Rodents and Non-Human Primates - - In a Mouse Model of ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that the Company presented new pre-clinical data highlighting its ...
RNA interference (RNAi) has broad potential as a therapeutic to reversibly silence any gene. To achieve the clinical potential of RNAi, delivery materials are required to transport short interfering ...
PeptiDream and Alnylam Announce Achievement of Key Milestone in siRNA Conjugate Discovery Collaboration Demonstrating Peptide-Ligand Mediated Targeted siRNA Delivery to Specific Extrahepatic Tissues ...
New York, USA – December 29, 2022 – BOC Sciences today announced the release of premium GalNAc-siRNA conjugation services to further support the delivery of siRNA drugs to the liver.
– New Pre-clinical Data from 'Alnylam5x15' Programs Including ALN-TTRsc for the Treatment of Transthyretin-Mediated Amyloidosis (ATTR) and ALN-AT3 for the Treatment of Hemophilia – CAMBRIDGE, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results